
Pharmaceutical
Eli Lilly to invest $6.5 billion in Houston plant for obesity pill
Eli Lilly is doubling down on U.S.-based drug manufacturing. The pharmaceutical giant announced Tuesday it will invest $6.5 billion in a new manufacturing facility in Houston, Texas, aimed at scaling production of its pipeline of small molecule drugs — most notably orforglipron, its experimental obesity pill. Expanding U.